Latest Manufacturing News

Noxopharm reported significant progress in its Sofra technology, highlighting enhanced cancer drug potential and preparations for a US FDA clinical trial, while managing tight cash reserves.

Radiopharm Theranostics reported robust Phase 2b results for RAD101 in brain metastases imaging, hitting 93% concordance with MRI and setting the stage for a U.S. Phase 3 trial. Meanwhile, its Phase 1 trial of RAD204 showed durable partial responses and good tolerability in advanced solid tumors.

Paradigm Biopharmaceuticals has strengthened its balance sheet with a combined $5.75 million cash inflow from Australian Government R&D tax incentives, supporting its pivotal Phase 3 osteoarthritis trial and regulatory efforts.

KMD Brands expects a 5% rise in FY26 sales and a more than doubling of EBITDA, while planning to divest its Southeast Asian manufacturing facility over the next year.

Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.

IDT Australia boosts its FY26 revenue guidance to $16.8 million, anticipating a substantial narrowing of EBITDA losses to under $1 million, driven by strong demand and cost efficiencies.

Recce Pharmaceuticals secured a non-binding term sheet with a major Middle Eastern pharma for its diabetic foot infection treatment and raised A$4 million to fund pivotal Phase 3 trials in Australia and Indonesia.

West Cobar Metals is gearing up for near-term drilling at its Cobar West copper project in NSW and high-grade scandium zones at the Salazar project in WA, aiming to unlock significant resource potential across both.

Cadoux Ltd and the SAFELOOP consortium have surpassed key performance and recycling targets in lithium-ion battery development, marking a world-first in commercial-scale use of recycled active materials enhanced by Cadoux's premiumHPA®. This breakthrough advances the pathway to gigafactory production and strengthens Cadoux's position in the EV battery supply chain.

Telix Pharmaceuticals reported a 21% year-on-year revenue jump to US$247 million in Q2 2026, buoyed by strong Precision Medicine sales and a new Regeneron partnership. The company also secured FDA alignment on a pivotal prostate cancer trial and expanded its manufacturing footprint.

Critical Minerals Group’s Pre-Feasibility Study for its Lindfield Vanadium Project delivers a robust $821 million pre-tax NPV and 26.6% IRR, setting the stage for a Definitive Feasibility Study and potential final investment decision in 2027.

Harris Technology (ASX: HT8) reported a 29% sales increase for FY26, driven by its refurbished technology division now contributing 58% of revenue and delivering higher margins. The company also secured a strategic equity conversion from FSP Technology, reinforcing its growth trajectory.